XOMA Revenue Jumps 39% in Fiscal Q2
(NASDAQ:XOMA), a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company’s revenue (GAAP) reached $13.1 million for Q2 2025, surpassing analyst GAAP estimates of $9.39 million. This was driven by substantial milestone payments and growing, but still limited, commercial royalties. Earnings per share (EPS) came in well above the $(0.15) loss analysts anticipated, at $0.44 diluted net income per share available to common stockholders (GAAP), though this fell short of last year’s Q2 2024 GAAP diluted net income per share of $0.84. Overall, the quarter highlighted XOMA’s strong deal flow and portfolio-building efforts, but recurring cash flow from product royalties remains behind milestone-driven results.
Source: Analyst estimates for the quarter provided by FactSet.
XOMA is a biotechnology company specializing in acquiring royalty interests in pharmaceutical and biotechnology products. Rather than developing drugs itself, it earns income from milestone payments and royalties on sales of partnered products. Its approach is to purchase the rights to potential future payments from a diverse group of drug assets across various therapeutic categories and clinical stages.
Source Fool.com
XOMA Corp. Aktie
Die XOMA Corp. Aktie verzeichnet starke Buy-Einschätzungen ohne jegliche Sell-Einschätzungen.
Die Community prognostiziert für XOMA Corp. ein Kursziel von 104 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 27.6 € bedeutet.
